Global cancer biomarkers market is estimated to have the CAGR of 11.8% during the forecast period 2016-2023. Biomarkers are molecules that identify and indicate any abnormal processes in an individual’s body. Molecules such as mRNA, DNA, metabolites, and proteins can serve as biomarkers. Cancer biomarkers are those proteins, genes, or other molecules that affect the growth of cancer cells and also regulate the response of a body to the growth of such cells. While some cancer biomarkers aid in predicting how aggressively the cancer is likely to grow and some help in identifying particular therapies required in treating cancer. Global cancer biomarkers market is driven by following factors:
- Rising cancer prevalence
- Enhanced accuracy and increase in speed of diagnosis
- Enhanced research
- FDA support for biomarker development
The key factor driving the growth of global cancer biomarkers market is the rising prevalence of cancer. World Health Organization stated that cancer is among the leading cause of mortality across the globe and recorded around 8.8 million deaths due to cancer, in 2015. The factors responsible for rising mortality due to cancer are tobacco accounting for 22% of cancer death, 1.69 million deaths due to lung cancer, 774 000 deaths due to colorectal, 754 000 deaths due to stomach cancer, 571 000 deaths due to breast cancer, and 788 000 deaths due to Liver cancer. The low fruit and vegetable intake, increasing tobacco intake, increasing alcohol abuse, high body mass index and lack of physical activity are also the factors causing cancers. Factors like hormonal imbalance, genetic and metabolic mutation, rising global geriatric population base, increasing awareness about the usage of biomarkers at various stages of cancers and rising demand for clinical diagnosis in first stage of cancers are driving the global cancer biomarkers market. However, poor reimbursement systems, high capital investment and low benefit-cost ratio and technical issues of sample collection and storage are the major factors restraining the growth of global cancer biomarkers market.
Advancing technology has enabled the ability of many potential biomarkers and has renewed interest in developing new biomarkers. Biomarkers used for cancer includes a broad range of biochemical entities, such as nucleic acids, protein, sugar, lipids, and small metabolites, cytogenetic and cytokine tic parameters. Owing to all these advantages along with rising prevalence of cancer, improper diet, increasing consumption of tobacco, less physical activities done and frequent sun & UV exposure, global cancer biomarkers market is expected to witness huge growth during the forecast period. However the major challenge of this market is proving clinical validity and utility of biomarker-based tests leading to their insufficient acceptance.
Source: OBRC Analysis
The global cancer biomarkers market is segmented into types, tumor, technologies and applications. Type segment of global cancer biomarkers market is further segmented into:
- Protein biomarkers
- Genetic bio markers
- Other biomarkers.
Tumor segment of global cancer biomarkers market is further segmented into:
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Lung cancer
- Other
Technology segment of global cancer biomarkers market is further segmented into:
- Immunoassays
- Genomics
- Protein omics
- Cytogenetics
- Imaging
- Bioinformatics
- Other omics
Applications segment of global cancer biomarkers market is further segmented into:
- Diagnostic
- Drug discovery
- Prognostics
- Risk assessment
- Other
The revenue for the above application segments is specific to the global cancer biomarkers market. However, the total revenue of these applications in general has been excluded from the scope of the report. Also, the total market revenue has been calculated by summing up type segment. Geographically, the global cancer biomarkers market is segmented into:
- North America (U.S. & Canada)
- Asia Pacific (China, India, Japan, Ro APAC)
- Europe (UK, France, Germany, RoE)
- Rest of World
North America is expected to hold the largest market share during the forecast period 2016-2023 due to rising demand for technically improvised healthcare infrastructure and rising need to detect, diagnose and manage various types of cancer and increasing awareness regarding the usage of biomarkers. Asia Pacific is expected to have the fastest growth rate. Rising demand for non-invasive diagnosis, less time in clinical trials and decline in expenditure of drug discovery & development processes have driven the cancer biomarker market in North America. In addition to this, increasing awareness related to the benefits of biomarkers in cancer treatment such as its ability to target patient-specific molecular structure and to enhance early stage cancer detection & screening and to detect the type of cancer are some few factors which are anticipated to additionally boost the market.
Global cancer biomarkers market is segmented on the basis of types, tumor, technologies involved and applications. Based on type, the cancer biomarker market is further segmented as protein biomarkers, genetic bio markers and other biomarkers. The protein based cancer biomarker is dominating the product segment. Key factors related to its large market share includes short assay development & monitoring time, reduced expenditure due to the lack of antibody development cost, and growing demand for absolute quantification & molecular specificity. On the basis of technology, the market is segmented into bioinformatics, imaging technology and omics technology. Increasing demand for modified treatment procedure; increasing technological advancements such as use of proteomic in cancer biomarker discovery, increasing demand for accurate & effective diagnostics procedure are some few factors that are driving the market growth. Moreover, favorable government initiatives which comprise growing investments pertaining to the development of cancer biomarkers are again expected to lift the market. On the basis of tumors, global cancer biomarker market is further segmented into breast cancer, colorectal cancer, prostate cancer, skin cancer, gastric, GIST, leukemia, lung and melanoma. Breast cancer & prostate cancer segments are the biggest consumers of biomarkers in global cancer biomarkers market.
The major market players of the global cancer biomarkers market are:
- ABBOTT LABORATORIES
- AMBRILIA BIOPHARMA
- BIOCUREX INC.
- AGENDIA BV
- AUREON LABORATORIES INC.
- OTHERS
Detailed analysis of these companies provided in this report comprises of overview, scot analysis, product portfolio, strategic initiative and strategic analysis.
These companies use various strategies such as mergers & acquisitions, collaboration, partnership and product launching. Merger, acquisition and product launch are the key strategies used by these companies. Example: In June 2016, Abbott Laboratories acquired medical-products maker St. Jude Medical Inc. to increase their product portfolio.
Why to buy the report:
This report will:
- Provide you the business strategies adopted by market player such as acquisitions as in June 2016, Abbott Laboratories acquired medical-products maker St. Jude Medical Inc. to increase their product portfolio.
- Provide in detail the different segments such as type, technologies, tumor and applications which affect the global cancer biomarkers market.
- Provide you the patent analysis of global cancer biomarkers market.
- Identify and understand the strengths, opportunities, challenges and threats of the global cancer biomarkers market.
- Provide revenues of major players of the market such as Biocurex Inc., Agendia BV, Aureon Laboratories Inc., and Beckman Coulter Inc.
- Provide you the various regulatory policies which affect the global cancer biomarkers market.
How we are different from others:
At Occams we provide an extensive portfolio which is comprehensive market analysis along with the market size, market share, and market segmentations. Our report on global cancer biomarkers market offers the longest chain of market segmentation covering major market segmentation based on type, tumor type, technologies and applications. The report tracks the major market trends in the global Cancer biomarkers market such as growing demand for modified treatment procedure, increasing technological advancements such as use of proteomic in cancer biomarker discovery, increasing demand for accurate & effective diagnostics procedure. For each market segments covered in global cancer biomarkers market report, we provide opportunity matrix, and DROC analysis, that enable the clear growth assessment across each market segment. The report discusses competitive landscape of the Cancer biomarkers industry, with giving extensive strategy analysis of more than 15 companies. Moreover, the report discusses various models such as 360 degree analysis, See Saw analysis, and Porter five force model and so on. For the high level analysis in the report we provide a comparative analysis of historic and current year data.
Key findings of the global cancer biomarkers market:
- North America had the largest revenue share in 2016.
- Protein based cancer biomarker was dominating the product type is due to short assay development & monitoring time, reduced expenditure due to the lack of antibody development cost, and growing demand for absolute quantification & molecular specificity.
- Omics based cancer biomarker is dominating in technology segment due to the factors like growing demand for modified treatment procedure, increasing technological advancements such as use of proteomic in cancer biomarker discovery, increasing demand for accurate & effective diagnostics procedure.
- Breast cancer & prostate cancer was observed to be the dominating segment in tumor type segment of biomarker.
- Mergers and acquisition is the key strategy adopted by the various market players of global cancer biomarkers market.
- Diagnostic is the major segment of applications.
